Pain has become one of medicine's most persistent contradictions. The body needs pain to signal injury, yet for millions of people that warning system can continue long after the original damage has healed. U.S. data found that 24.3% of adults had chronic pain, while 8.5% experienced pain that frequently limited their life or work activities.
The scale of the problem is forcing a rethink of how pain is treated. In May 2026, the U.S. Food and Drug Administration issued draft guidance specifically addressing the development of non-opioid analgesics for chronic pain, reflecting the continuing need for new approaches in a field where therapeutic options remain constrained. The regulatory push follows a broader shift in pain medicine, including the 2025 approval of Journavx, the first drug in a new class of non-opioid medicines for moderate to severe acute pain. However, drugs for chronic pain continue to partially and ineffectively treat pain symptoms.
